SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian's stock is trending amidst discussions about narrowed delivery guidance and community speculation on its potential impact. Investors are weighing positive factors such as increased deliveries and the upcoming R2 vehicle against concerns about tax credit expiration and competition. Community members are actively debating the company's future prospects and potential catalysts, like the VW partnership.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community anticipates the Q3 delivery report, with discussions focusing on whether the numbers will justify the stock's valuation and if the expiring EV tax credit has pulled sales forward. Bullish sentiment anticipates a delivery beat and a continued rally, while bears are wary of a potential "sell the news" event and question the company's fundamentals. Many are pointing to TSLA not being a car company but a "technology" company to justify any sales numbers.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending due to positive topline results from its Phase 2 schizophrenia study, with community members highlighting the potential disease-modifying effects of ANAVEX3-71. Discussions also revolve around the upcoming CHMP opinion for Alzheimer's, expected in November, and its potential impact. Some traders speculate on a short squeeze, while others analyze the safety data and potential market value of AVXL's drugs.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing community backlash and a potential boycott after concerns about its content, particularly regarding children's programming and transgender themes, gained traction on social media and sparked commentary from public figures. Some users are canceling subscriptions and advocating for others to do the same, citing concerns about "woke" content and perceived agendas, while others defend the platform's diversity and the right to choose content. The controversy coincides with tariff concerns, contributing to market volatility around the stock.

Angel Studios, Inc. is a values-based distribution company for stories that amplify light to mainstream audiences. The company is headquartered in Provo, UT.

Angel Studios Inc. - Ordinary Shares - Class A

Angel Studios Inc

Angel Studios ($ANGX) is trending due to a recent surge, sparking discussions about its potential as an alternative to mainstream streaming services like Netflix. Community members are weighing in on factors that could be contributing to the increase, including possible celebrity endorsements and the company's unique community-driven model. The stock's volatility and potential for further growth are also hot topics.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members highlight its focus on culture, freedom, and global connection. Some users are drawing comparisons to Bitcoin, emphasizing Weedcoin's potential and unique utility. Community discussions also mention its underlying technology and potential for real-world applications.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber ($WYFI) is trending as chatter picks up following analyst coverage and price target upgrades, with community members highlighting the low float and potential for significant upside. Bullish sentiment surrounds the company's position in the high-demand AI data center sector and anticipation for news regarding its North Carolina facility. Some investors are drawing comparisons to other high-flying data center stocks, while others see $WYFI as a compelling play relative to its parent company, $BTBT.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending following news that Berkshire Hathaway will acquire its OxyChem unit for $9.7 billion, marking Buffett's largest deal in years. The community is discussing the implications for OXY's debt reduction and potential stock buybacks, with some anticipating a significant price increase. Some investors believe the deal unlocks shareholder value, while others express concerns about selling assets.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors discuss the company's potential, highlighting progress on commissioning new data centers and anticipating a hyperscaler deal announcement. Bullish sentiment is high, with comparisons to other successful AI and data center stocks like NVDA and NBIS. Some traders are also focusing on potential upcoming earnings and the possibility of a short squeeze.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Kazia Therapeutics

KZIA is trending due to promising preclinical data suggesting its drug paxalisib can overcome immunotherapy resistance in triple-negative breast cancer, potentially enhancing treatment effectiveness. Community discussions revolve around the significance of these findings and whether it could lead to future gains. Some traders are wary of the stock's history and potential for dilution while others highlight the positive news and low float.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business...

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services Citius Pharmaceuticals and Citius Oncology Announce Unique...

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch...

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives...

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update...

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides...

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer...

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment...

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology...

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and...

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Citius Oncology Inc.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

CTOR
Citius Oncology Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CTOR News

CTOR Citius Oncology Inc.